Inhibition of NF-κB Signaling Alters Acute Myelogenous Leukemia Cell Transcriptomics.

ABSTRACT: Acute myelogenous leukemia (AML) is an aggressive hematological malignancy. The pathophysiology of the disease depends on cytogenetic abnormalities, gene mutations, aberrant gene expressions, and altered epigenetic regulation. Although new pharmacological agents have emerged during the last years, the prognosis is still dismal and new therapeutic strategies are needed. The transcription factor nuclear factor-κB (NF-κB) is regarded a possible therapeutic target. In this study, we investigated the alterations in the global gene expression profile (GEP) in primary AML cells derived from 16 consecutive patients after exposure to the NF-κB inhibitor BMS-345541. We identified a profound and highly discriminative transcriptomic profile associated with NF-κB inhibition. Bioinformatical analyses id

SUBMITTER: Reikvam H 

PROVIDER: S-EPMC7408594 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature